Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
9.60
-0.19 (-1.94%)
Sep 16, 2025, 4:00 PM EDT - Market closed
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Cartesian Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $40, which forecasts a 316.67% increase in the stock price over the next year. The lowest target is $38 and the highest is $42.
Price Target: $40 (+316.67%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 9, 2025.
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 4 | 4 | 3 |
| Buy | 1 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Initiates $38 | Buy | Initiates | $38 | +295.83% | Jul 9, 2025 |
| Needham | Needham | Strong Buy Maintains $41 → $40 | Strong Buy | Maintains | $41 → $40 | +316.67% | May 8, 2025 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +327.08% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +316.67% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $40 | Strong Buy | Maintains | $45 → $40 | +316.67% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
1.90M
from 38.91M
Decreased by -95.11%
Revenue Next Year
535.50K
from 1.90M
Decreased by -71.86%
EPS This Year
-2.18
from -4.49
EPS Next Year
-3.63
from -2.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.3M | 1.7M | |||
| Avg | 1.9M | 535,500 | |||
| Low | 1.1M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -86.5% | -11.7% | |||
| Avg | -95.1% | -71.9% | |||
| Low | -97.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.54 | -2.19 | |||
| Avg | -2.18 | -3.63 | |||
| Low | -3.43 | -4.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.